{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:37:15Z","timestamp":1791333435717,"version":"4.3.1"},"reference-count":194,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente - Linea 4 - Progetto 2 - INMI L. Spallanzani I.R.C.C.S"],"award-info":[{"award-number":["Ricerca Corrente - Linea 4 - Progetto 2 - INMI L. Spallanzani I.R.C.C.S"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Tuberculosis (TB) is the leading cause of death in the world from an infectious disease. Its etiologic agent, the\n                    <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                    (Mtb), is a slow-growing bacterium that has coexisted in humans for thousands of years. According to the World Health Organization, 10.6 million new cases of TB and over 1 million deaths were reported in 2022. It is widely recognized that patients affected by chronic autoimmune arthritis such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) have an increased incidence rate of TB disease compared to the general population. As conceivable, the risk is associated with age \u226565 years and is higher in endemic regions, but immunosuppressive therapy plays a pivotal role. Several systematic reviews have analysed the impact of anti-TNF-\u03b1 agents on the risk of TB in patients with chronic autoimmune arthritis, as well as for other biologic disease-modifying immunosuppressive anti-rheumatic drugs (bDMARDs) such as rituximab, abatacept, tocilizumab, ustekinumab, and secukinumab. However, the data are less robust compared to those available with TNF-\u03b1 inhibitors. Conversely, data on anti-IL23 agents and JAK inhibitors (JAK-i), which have been more recently introduced for the treatment of RA and PsA\/AS, are limited. TB screening and preventive therapy are recommended in Mtb-infected patients undergoing bDMARDs and targeted synthetic (ts)DMARDs. In this review, we evaluate the current evidence from randomized clinical trials, long-term extension studies, and real-life studies regarding the risk of TB in patients with RA, PsA, and AS treated with bDMARDs and tsDMARDs. According to the current evidence, TNF-\u03b1 inhibitors carry the greatest risk of TB progression among bDMARDs and tsDMARDs, such as JAK inhibitors and anti-IL-6R agents. The management of TB screening and the updated preventive therapy are reported.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2025.1494283","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T01:34:57Z","timestamp":1738546497000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["Management of tuberculosis risk, screening and preventive therapy in patients with chronic autoimmune arthritis undergoing biotechnological and targeted immunosuppressive agents"],"prefix":"10.3389","volume":"16","author":[{"given":"Andrea","family":"Picchianti-Diamanti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Aiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"De Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Battista","family":"Migliori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"Goletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"key":"B1","unstructured":"Global tuberculosis report\n          \n          2023"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-023-17495-6","article-title":"Global, regional and national trends in tuberculosis incidence and main risk factors: a study using data from 2000 to 2021","volume":"24","author":"Bai","year":"2024","journal-title":"BMC Public Health"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2018.1483238","article-title":"Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs","volume":"16","author":"Goletti","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1183\/2312508X.10024022","article-title":"Host\u2013pathogen interactions in the context of tuberculosis infection and disease","author":"Goletti","year":"2023"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/microbiolspec.tnmi7-0032-2016","article-title":"Pulmonary tuberculosis","volume":"5","author":"Lyon","year":"2017","journal-title":"Microbiol Spectr"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2022.02.047","article-title":"The role of IGRA in the diagnosis of tuberculosis infection, differentiating from active tuberculosis, and decision making for initiating treatment or preventive therapy of tuberculosis infection","volume":"124","author":"Goletti","year":"2022","journal-title":"Int J Infect Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00021-18","article-title":"Incipient and subclinical tuberculosis: a clinical review of early stages and progression of infection","volume":"31","author":"Drain","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(24)00028-6","article-title":"Classification of early tuberculosis states to guide research for improved care and prevention: an international Delphi consensus exercise","volume":"12","author":"Coussens","year":"2024","journal-title":"Lancet Respir Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"210079","DOI":"10.1183\/20734735.0079-2021","article-title":"The definition of tuberculosis infection based on the spectrum of tuberculosis disease","volume":"17","author":"Migliori","year":"2021","journal-title":"Breathe (Sheff)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1244556","article-title":"Initial immune response after exposure to Mycobacterium tuberculosis or to SARS-COV-2: similarities and differences","volume":"14","author":"Aiello","year":"2023","journal-title":"Front Immunol"},{"key":"B11","article-title":"Local production of nitric oxide in patients with tuberculosis","volume":"8","author":"Sch\u00f6n","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1210500109","article-title":"Autophagy protects against active tuberculosis by suppressing bacterial burden and inflammation","volume":"109","author":"Castillo","year":"2012","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis226","article-title":"Specific T cells restore the autophagic flux inhibited by Mycobacterium tuberculosis in human primary macrophages","volume":"205","author":"Petruccioli","year":"2012","journal-title":"J Infect Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4161\/auto.20881","article-title":"ESX-1 dependent impairment of autophagic flux by Mycobacterium tuberculosis in human dendritic cells","volume":"8","author":"Romagnoli","year":"2012","journal-title":"Autophagy"},{"key":"B15","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41419-018-0640-8","article-title":"Clinical isolates of the modern Mycobacterium tuberculosis lineage 4 evade host defense in human macrophages through eluding IL-1\u03b2-induced autophagy","volume":"9","author":"Romagnoli","year":"2018","journal-title":"Cell Death Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-01121-x","article-title":"The immunoregulatory landscape of human tuberculosis granulomas","volume":"23","author":"McCaffrey","year":"2022","journal-title":"Nat Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3412","article-title":"Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing","volume":"20","author":"Lin","year":"2014","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00084","article-title":"Mycobacterial dormancy systems and host responses in tuberculosis","volume":"8","author":"Peddireddy","year":"2017","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004603","article-title":"Variability in tuberculosis granuloma T cell responses exists, but a balance of pro- and anti-inflammatory cytokines is associated with sterilization","volume":"11","author":"Gideon","year":"2015","journal-title":"PloS Pathog"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2007.02719.x","article-title":"Immunological decision-making: how does the immune system decide to mount a helper T-cell response","volume":"123","author":"Kaiko","year":"2008","journal-title":"Immunology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109696","article-title":"CD4 T cell help prevents CD8 T cell exhaustion and promotes control of Mycobacterium tuberculosis infection","volume":"36","author":"Lu","year":"2021","journal-title":"Cell Rep"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e142014, 142014","DOI":"10.1172\/JCI142014","article-title":"Tissue-resident-like CD4+ T cells secreting IL-17 control Mycobacterium tuberculosis in the human lung","volume":"131","author":"Ogongo","year":"2021","journal-title":"J Clin Invest"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/sji.13085","article-title":"Immuno-genetic importance of Th17 in susceptibility to TB","volume":"94","author":"Rapolu","year":"2021","journal-title":"Scandinavian J Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1276-2","article-title":"Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis","volume":"570","author":"Ardain","year":"2019","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg7673","article-title":"Exaggerated IL-17A activity in human in vivo recall responses discriminates active tuberculosis from latent infection and cured disease","volume":"13","author":"Pollara","year":"2021","journal-title":"Sci Transl Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.3.1416","article-title":"Cutting edge: IFN-gamma regulates the induction and expansion of IL-17-producing CD4 T cells during mycobacterial infection","volume":"177","author":"Cruz","year":"2006","journal-title":"J Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/microbiolspec.tbtb2-0006-2016","article-title":"Regulation of immunity to tuberculosis","volume":"4","author":"Brighenti","year":"2016","journal-title":"Microbiol Spectr"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2023.04.007","article-title":"Disseminated mycobacterial infections following TNF inhibitor use revealing inborn errors of immunity","volume":"131","author":"Squire","year":"2023","journal-title":"Int J Infect Dis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3899\/jrheum.140103","article-title":"Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-\u03b1 (TNF-\u03b1) targeted biologics and recently licensed TNF-\u03b1 inhibitors: data from clinical trials and national registries","volume":"91","author":"Cantini","year":"2014","journal-title":"J Rheumatol Suppl"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0194430","article-title":"TNF-\u03b1 blockade impairs in vitro tuberculous granuloma formation and down modulate Th1, Th17 and Treg cytokines","volume":"13","author":"da Silva","year":"2018","journal-title":"PloS One"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17552-1","article-title":"Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies","volume":"364","author":"Dorman","year":"2004","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2013.0050","article-title":"Innate defects of the IL-12\/IFN-\u03b3 Axis in susceptibility to infections by mycobacteria and salmonella","volume":"34","author":"Ramirez-Alejo","year":"2014","journal-title":"J Interferon Cytokine Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2021.07.001","article-title":"Mycobacterial diseases in patients with inborn errors of immunity","volume":"72","author":"Boisson-Dupuis","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.22.0685","article-title":"Epidemiology, pathogenesis, clinical presentation and management of TB in patients with HIV and diabetes","volume":"27","author":"Goletti","year":"2023","journal-title":"Int J Tuberc Lung Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12272","article-title":"Inherited and acquired immunodeficiencies underlying tuberculosis in childhood","volume":"264","author":"Boisson-Dupuis","year":"2015","journal-title":"Immunol Rev"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20060085","article-title":"X-linked susceptibility to mycobacteria is caused by mutations in NEMO impairing CD40-dependent IL-12 production","volume":"203","author":"Filipe-Santos","year":"2006","journal-title":"J Exp Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2021.04.007","article-title":"Inborn errors of IL-6 family cytokine responses","volume":"72","author":"Chen","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.09.009","article-title":"Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity","volume":"25","author":"Minegishi","year":"2006","journal-title":"Immunity"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07866-3","article-title":"Tuberculosis in otherwise healthy adults with inherited TNF deficiency","volume":"633","author":"Arias","year":"2024","journal-title":"Nature"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2006.01.008","article-title":"The role of antibody-mediated immunity in defense against Mycobacterium tuberculosis: advances toward a novel vaccine strategy","volume":"86","author":"Glatman-Freedman","year":"2006","journal-title":"Tuberculosis (Edinb)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.11.3.514","article-title":"Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis","volume":"11","author":"Glatman-Freedman","year":"1998","journal-title":"Clin Microbiol Rev"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.640168","article-title":"B-cells and antibodies as contributors to effector immune responses in tuberculosis","volume":"12","author":"Rijnink","year":"2021","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-6111-1_12","article-title":"The role of B cells and humoral immunity in Mycobacterium tuberculosis infection","volume":"783","author":"Kozakiewicz","year":"2013","journal-title":"Adv Exp Med Biol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.smim.2014.10.005","article-title":"The role of B cells and humoral immunity in Mycobacterium tuberculosis infection","volume":"26","author":"Chan","year":"2014","journal-title":"Semin Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0439-x","article-title":"A multi-cohort study of the immune factors associated with M. tuberculosis infection outcomes","volume":"560","author":"Roy Chowdhury","year":"2018","journal-title":"Nature"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005687","article-title":"Patients with tuberculosis have a dysfunctional circulating B-cell compartment, which normalizes following successful treatment","volume":"12","author":"Joosten","year":"2016","journal-title":"PloS Pathog"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-000935","article-title":"Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study","volume":"5","author":"Mehta","year":"2019","journal-title":"RMD Open"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.15.0283","article-title":"Risk of developing active tuberculosis in rheumatoid arthritis patients on adalimumab in Japan","volume":"20","author":"Watanabe","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"B49","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/art.21705","article-title":"Glucocorticoid use, other associated factors, and the risk of tuberculosis","volume":"55","author":"Jick","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/art.24476","article-title":"Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada","volume":"61","author":"Brassard","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.201251","article-title":"Tuberculosis in biologic-na\u00efve patients with rheumatoid arthritis: risk factors and tuberculosis characteristics","volume":"48","author":"Sundbaum","year":"2021","journal-title":"J Rheumatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012567","article-title":"Risk of tuberculosis in patients treated with TNF-\u03b1 antagonists: a systematic review and meta-analysis of randomised controlled trials","volume":"7","author":"Zhang","year":"2017","journal-title":"BMJ Open"},{"key":"B53","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3899\/jrheum.140102","article-title":"Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance","volume":"91","author":"Cantini","year":"2014","journal-title":"J Rheumatol Suppl"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2010.12.004","article-title":"Incidence of tuberculosis in patients with rheumatoid arthritis. A systematic literature review","volume":"78","author":"Baronnet","year":"2011","journal-title":"Joint Bone Spine"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002726","article-title":"Systematic literature review informing the 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"8","author":"Fragoulis","year":"2022","journal-title":"RMD Open"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/microbiolspec.TNMI7-0026-2016","article-title":"Biologic agents and tuberculosis","volume":"4","author":"Dobler","year":"2016","journal-title":"Microbiol Spectr"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20930116","article-title":"Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors","volume":"12","author":"Evangelatos","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-022-02062-7","article-title":"National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic disease modifying antirheumatic drugs (DMARDs)","volume":"134","author":"Rath","year":"2022","journal-title":"Wien Klin Wochenschr"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/path.2287","article-title":"TNF-mediated inflammatory disease","volume":"214","author":"Bradley","year":"2008","journal-title":"J Pathol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/03946320140270S101","article-title":"The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases","volume":"27","author":"Blandizzi","year":"2014","journal-title":"Int J Immunopathol Pharmacol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cyto.2016.08.014","article-title":"Molecular mechanisms of action of anti-TNF-\u03b1 agents - Comparison among therapeutic TNF-\u03b1 antagonists","volume":"101","author":"Mitoma","year":"2018","journal-title":"Cytokine"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2009.01.002","article-title":"Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor","volume":"131","author":"Kaymakcalan","year":"2009","journal-title":"Clin Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.301.2.418","article-title":"Binding and functional comparisons of two types of tumor necrosis factor antagonists","volume":"301","author":"Scallon","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1086\/421494","article-title":"Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor","volume":"39","author":"Mohan","year":"2004","journal-title":"Clin Infect Dis"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.152223","article-title":"Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study","volume":"71","author":"Baranauskaite","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1002\/art.20568","article-title":"Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial","volume":"50","author":"St Clair","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/art.20159","article-title":"Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate","volume":"50","author":"Maini","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1002\/art.21734","article-title":"The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial","volume":"54","author":"Westhovens","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/art.20217","article-title":"Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B72","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/art.21519","article-title":"The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100208","article-title":"Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER","volume":"37","author":"van der Heijde","year":"2010","journal-title":"J Rheumatol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100752","article-title":"Clinical consequences of delayed addition of adalimumab to methotrexate therapy over 5 years in patients with rheumatoid arthritis","volume":"38","author":"Keystone","year":"2011","journal-title":"J Rheumatol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092767","article-title":"Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)","volume":"68","author":"Mease","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202533","article-title":"Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial","volume":"73","author":"Huang","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61811-X","article-title":"Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial","volume":"381","author":"Smolen","year":"2013","journal-title":"Lancet"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.038349","article-title":"A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs","volume":"65","author":"Klareskog","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes125","article-title":"Continuous efficacy of etanercept in severe and advanced ankylosing spondylitis: results from a 12-week open-label extension of the SPINE study","volume":"51","author":"Dougados","year":"2012","journal-title":"Rheumatol (Oxford)"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3899\/jrheum.140095","article-title":"Biologics and tuberculosis risk: the rise and fall of an old disease and its new resurgence","volume":"91","author":"Cantini","year":"2014","journal-title":"J Rheumatol Suppl"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21788","article-title":"Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in Phase III clinical trials","volume":"65","author":"Hsia","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B82","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/annrheumdis-2013-203660","article-title":"Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials","volume":"74","author":"Bykerk","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex174","article-title":"Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA","volume":"56","author":"van der Heijde","year":"2017","journal-title":"Rheumatol (Oxford)"},{"key":"B84","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report","volume":"48","author":"G\u00f3mez-Reino","year":"2003","journal-title":"Arthritis Rheum"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1002\/art.21137","article-title":"Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden","volume":"52","author":"Askling","year":"2005","journal-title":"Arthritis Rheum"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/art.21386","article-title":"Infections in patients with rheumatoid arthritis treated with biologic agents","volume":"52","author":"Listing","year":"2005","journal-title":"Arthritis Rheum"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150057","article-title":"The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-\u03b1 Antagonist: A metaanalysis of both randomized controlled trials and registry\/cohort studies","volume":"42","author":"Ai","year":"2015","journal-title":"J Rheumatol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.750068","article-title":"Pleiotropic effect of IL-6 produced by B-lymphocytes during early phases of adaptive immune responses against TB infection","volume":"13","author":"Linge","year":"2022","journal-title":"Front Immunol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3855\/jidc.10949","article-title":"Relevance of TNF-\u03b1, IL-6 and IRAK1 gene expression for assessing disease severity and therapy effects in tuberculosis patients","volume":"13","author":"Buha","year":"2019","journal-title":"J Infect Dev Ctries"},{"key":"B91","article-title":"Role of interleukin-6 in the induction of protective T cells during mycobacterial infections in mice","volume":"82","author":"Appelberg","year":"1994","journal-title":"Immunology"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.68.6.3322-3326.2000","article-title":"Interleukin-6 induces early gamma interferon production in the infected lung but is not required for generation of specific immunity to Mycobacterium tuberculosis infection","volume":"68","author":"Saunders","year":"2000","journal-title":"Infect Immun"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu172","article-title":"Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies","volume":"53","author":"Souto","year":"2014","journal-title":"Rheumatol (Oxford)"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212825","article-title":"Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"77","author":"Rutherford","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2010.154","article-title":"The Japanese experience with biologic therapies for rheumatoid arthritis","volume":"6","author":"Takeuchi","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13075-022-02842-6","article-title":"Comparison of developing tuberculosis following tumor necrosis factor inhibition and interleukin-6 inhibition in patients with rheumatoid arthritis: a nationwide observational study in South Korea, 2013-2018","volume":"24","author":"Jung","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/srep36923","article-title":"Controlled Mycobacterium tuberculosis infection in mice under treatment with anti-IL-17A or IL-17F antibodies, in contrast to TNF\u03b1 neutralization","volume":"6","author":"Segueni","year":"2016","journal-title":"Sci Rep"},{"key":"B98","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1600-065X.2008.00702.x","article-title":"The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis","volume":"226","author":"Cooper","year":"2008","journal-title":"Immunol Rev"},{"key":"B99","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.cyto.2007.11.022","article-title":"IL-23 and IL-17 in tuberculosis","volume":"41","author":"Khader","year":"2008","journal-title":"Cytokine"},{"key":"B100","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jamadermatol.2020.3257","article-title":"Association of secukinumab treatment with tuberculosis reactivation in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis","volume":"157","author":"Elewski","year":"2021","journal-title":"JAMA Dermatol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"adv00698","DOI":"10.2340\/actadv.v102.563","article-title":"Long-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance data","volume":"102","author":"Gottlieb","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-023-06630-8","article-title":"Safety of secukinumab in the treatment of patients with axial spondyloarthritis and concurrent hepatitis B virus infection or latent tuberculosis infection","volume":"42","author":"Liu","year":"2023","journal-title":"Clin Rheumatol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.radcr.2022.10.032","article-title":"Active pulmonary tuberculosis in a patient with secukinumab treatment","volume":"18","author":"Ngoc","year":"2023","journal-title":"Radiol Case Rep"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23738","article-title":"Safety of ixekizumab in patients with psoriatic arthritis: results from a pooled analysis of three clinical trials","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003855","article-title":"Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL","volume":"10","author":"Coates","year":"2024","journal-title":"RMD Open"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223595","article-title":"Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials","volume":"82","author":"van der Heijde","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1002\/art.42282","article-title":"Safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: three-year results from a phase IIb randomized controlled trial and its open-label extension study","volume":"74","author":"Baraliakos","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"B108","article-title":"Interleukin-12 and interleukin-23 inhibition in psoriatic arthritis","volume":"33","author":"Johnsson","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204655","article-title":"Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B111","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1136\/ard-2022-222879","article-title":"Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study","volume":"82","author":"Gossec","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2017.02.001","article-title":"Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasis","volume":"3","author":"Lynch","year":"2017","journal-title":"JAAD Case Rep"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac607","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study","volume":"62","author":"Kristensen","year":"2023","journal-title":"Rheumatol (Oxford)"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-024-00657-2","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 100-week results from the KEEPsAKE 2 randomized clinical trial","volume":"11","author":"\u00d6st\u00f6r","year":"2024","journal-title":"Rheumatol Ther"},{"key":"B117","doi-asserted-by":"publisher","first-page":"annrheumdis","DOI":"10.1136\/annrheumdis-2022-222628","article-title":"Guselkumab for treating immune checkpoint inhibitor-induced psoriatic arthritis","volume":"81","author":"Takeda","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19406","article-title":"No tuberculosis reactivations in psoriasis patients initiating new generation biologics despite untreated latent tuberculosis infection: Multicenter case series of 35 patients","volume":"38","author":"Manzanares","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"adv00821","DOI":"10.2340\/actadv.v102.1982","article-title":"Risk of reactivation of latent tuberculosis in psoriasis patients on biologic therapies: A retrospective cohort from a tertiary care centre in northern Italy","volume":"102","author":"Mastorino","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-024-00845-4","article-title":"Treatment of psoriasis patients with latent tuberculosis using IL-17 and IL-23 inhibitors: A retrospective, multinational, multicentre study","volume":"25","author":"Torres","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14199","article-title":"Successful use of guselkumab in the treatment of severe hidradenitis suppurativa","volume":"45","author":"Kearney","year":"2020","journal-title":"Clin Exp Dermatol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s13555-024-01130-2","article-title":"Interleukin-17A inhibitors in patients with psoriasis and tuberculosis infection: A 2-year prospective study on safety without preventive treatment","volume":"14","author":"He","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1002\/art.10947","article-title":"Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy","volume":"48","author":"Silverman","year":"2003","journal-title":"Arthritis Rheum"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090856","article-title":"Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials","volume":"37","author":"van Vollenhoven","year":"2010","journal-title":"J Rheumatol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120573","article-title":"Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study","volume":"39","author":"Keystone","year":"2012","journal-title":"J Rheumatol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/rheumatology\/key023","article-title":"Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"57","author":"Rutherford","year":"2018","journal-title":"Rheumatol (Oxford)"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201956","article-title":"Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients","volume":"72","author":"van Vollenhoven","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-015-3099-3","article-title":"Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom","volume":"34","author":"Nisar","year":"2015","journal-title":"Clin Rheumatol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu457","article-title":"Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting","volume":"54","author":"Tarkiainen","year":"2015","journal-title":"Rheumatol (Oxford)"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1002\/art.27555","article-title":"Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry","volume":"62","author":"Gottenberg","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B132","doi-asserted-by":"publisher","first-page":"R75","DOI":"10.1186\/ar3337","article-title":"Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)","volume":"13","author":"Tony","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"B133","doi-asserted-by":"publisher","first-page":"R80","DOI":"10.1186\/ar4521","article-title":"Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients","volume":"16","author":"Wendler","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12367","article-title":"Abatacept (cytotoxic T lymphocyte antigen 4-immunoglobulin) improves B cell function and regulatory T cell inhibitory capacity in rheumatoid arthritis patients non-responding to anti-tumour necrosis factor-\u03b1 agents","volume":"177","author":"Picchianti Diamanti","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120906","article-title":"Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program","volume":"40","author":"Weinblatt","year":"2013","journal-title":"J Rheumatol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152313","article-title":"Infection outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: Results from a 10-year international post-marketing study","volume":"64","author":"Simon","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2019.1612872","article-title":"Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice","volume":"18","author":"Cantini","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052638","article-title":"Inhibition of phosphodiesterase-4 in psoriatic arthritis and inflammatory bowel diseases","volume":"22","author":"Picchianti-Diamanti","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20287","article-title":"Treatment of psoriasis with biologic and non-biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: Recommendations from a SPIN-FRT expert consensus","volume":"39","author":"Torres","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000669","article-title":"Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies","volume":"4","author":"Gladman","year":"2018","journal-title":"RMD Open"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S239511","article-title":"Herpes zoster and tuberculosis risk with apremilast compared to biologics, DMARDs and corticosteroids to treat psoriasis and psoriatic arthritis","volume":"12","author":"Hagberg","year":"2020","journal-title":"Clin Epidemiol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key276","article-title":"New players in the field of immune-mediated diseases, beyond rheumatoid arthritis","volume":"58","author":"Fragoulis","year":"2019","journal-title":"Rheumatol (Oxford)"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1513","article-title":"Preferential inhibition of JAK1 relative to JAK3 by upadacitinib: exposure-response analyses of ex vivo data from 2 phase 1 clinical trials and comparison to tofacitinib","volume":"60","author":"Mohamed","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"B144","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13075-019-1964-1","article-title":"Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations","volume":"21","author":"McInnes","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis269","article-title":"Risk of tuberculosis reactivation with tofacitinib (CP-690550)","volume":"205","author":"Maiga","year":"2012","journal-title":"J Infect Dis"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210457","article-title":"Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207319","article-title":"Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-022-06205-z","article-title":"Real-world evidence of the effectiveness and safety of generic tofacitinib in rheumatoid arthritis patients: a retrospective, single-centre analysis from Western India","volume":"41","author":"Phatak","year":"2022","journal-title":"Clin Rheumatol"},{"key":"B149","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3899\/jrheum.171361","article-title":"Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment","volume":"46","author":"Smolen","year":"2019","journal-title":"J Rheumatol"},{"key":"B150","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/1756-185X.13748","article-title":"Safety of baricitinib in East Asian patients with moderate-to-severe active rheumatoid arthritis: An integrated analysis from clinical trials","volume":"23","author":"Chen","year":"2020","journal-title":"Int J Rheum Dis"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"Lancet"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218510","article-title":"Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme","volume":"80","author":"Cohen","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N Engl J Med"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218870","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222608","article-title":"Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial","volume":"81","author":"van der Heijde","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13020401","article-title":"Efficacy and safety of upadacitinib in rheumatoid arthritis: real-life experience from a prospective longitudinal multicentric study","volume":"13","author":"Baldi","year":"2024","journal-title":"J Clin Med"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-024-00712-y","article-title":"Clinical and ultrasonographic remission in bio-na\u00efve and bio-failure patients with rheumatoid arthritis at 24 weeks of upadacitinib treatment: the UPARAREMUS real-life study","volume":"11","author":"Picchianti Diamanti","year":"2024","journal-title":"Rheumatol Ther"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial","volume":"80","author":"Combe","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221051","article-title":"Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years","volume":"81","author":"Winthrop","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B162","unstructured":"WHO consolidated guidelines on tuberculosis Module 1: prevention - tuberculosis preventive treatment"},{"key":"B163","doi-asserted-by":"publisher","first-page":"190","DOI":"10.5588\/ijtld.21.0753","article-title":"Clinical standards for the diagnosis, treatment and prevention of TB infection","volume":"26","author":"Migliori","year":"2022","journal-title":"Int J Tuberc Lung Dis"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2023.07.014","article-title":"Update on the diagnosis of tuberculosis","volume":"30","author":"Kontsevaya","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2023.2240230","article-title":"Research tests for the diagnosis of tuberculosis infection","volume":"23","author":"Alonzi","year":"2023","journal-title":"Expert Rev Mol Diagn"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00107608","article-title":"QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases","volume":"33","author":"Bartalesi","year":"2009","journal-title":"Eur Respir J"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2018.09.005","article-title":"The usefulness of routine chest radiograph examinations in patients treated with TNF inhibitors for inflammatory arthritis in South Korea","volume":"143","author":"Kang","year":"2018","journal-title":"Respir Med"},{"key":"B168","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jped.2023.02.002","article-title":"Tuberculosis preventive treatment in children and adolescents: an observational study of secondary data","volume":"99","author":"Tahan","year":"2023","journal-title":"J Pediatr (Rio J)"},{"key":"B169","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13063-022-07062-6","article-title":"Isoniazid preventive therapy completion in children under 5 years old who are contacts of tuberculosis cases in Lima, Peru: study protocol for an open-label, cluster-randomized superiority trial","volume":"24","author":"Otero","year":"2023","journal-title":"Trials"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003436","article-title":"Efficacy, safety, and tolerability of isoniazid preventive therapy for tuberculosis in people living with HIV","volume":"37","author":"Jagi","year":"2023","journal-title":"AIDS"},{"key":"B171","article-title":"Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis","volume":"60","year":"1982","journal-title":"Bull World Health Organ"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1986.03370120057023","article-title":"Preventive therapy with isoniazid. Cost-effectiveness of different durations of therapy","volume":"255","author":"Snider","year":"1986","journal-title":"JAMA"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.11.1014","article-title":"Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic","volume":"281","author":"Nolan","year":"1999","journal-title":"JAMA"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200303-390OC","article-title":"Use of isoniazid for latent tuberculosis infection in a public health clinic","volume":"168","author":"LoBue","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"B175","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ijid.2016.11.006","article-title":"Preventive therapy for latent tuberculosis infection-the promise and the challenges","volume":"56","author":"Fox","year":"2017","journal-title":"Int J Infect Dis"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1111\/jpc.14359","article-title":"Barriers to the implementation of isoniazid preventive therapy for tuberculosis in children in endemic settings: A review","volume":"55","author":"Grace","year":"2019","journal-title":"J Paediatr Child Health"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2018.05.013","article-title":"Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan","volume":"111","author":"Sun","year":"2018","journal-title":"Tuberculosis (Edinb)"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8060812","article-title":"Isoniazid concentration and NAT2 genotype predict risk of systemic drug reactions during 3HP for LTBI","volume":"8","author":"Lee","year":"2019","journal-title":"J Clin Med"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad246","article-title":"A systematic review and meta-analysis of tuberculous preventative therapy adverse events","volume":"77","author":"Melnychuk","year":"2023","journal-title":"Clin Infect Dis"},{"key":"B181","unstructured":"Tuberculosis preventive treatment: rapid communication\n          \n          2024"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i26.3291","article-title":"Fluoroquinolones for the treatment of latent Mycobacterium tuberculosis infection in liver transplantation","volume":"25","author":"Silva","year":"2019","journal-title":"World J Gastroenterol"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.855141","article-title":"Prevalence of metabolic syndrome in patients with rheumatoid arthritis: an updated systematic review and meta-analysis","volume":"9","author":"Cai","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac003","article-title":"Whole-blood 3-gene signature as a decision aid for rifapentine-based tuberculosis preventive therapy","volume":"75","author":"Huang","year":"2022","journal-title":"Clin Infect Dis"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13913","article-title":"Prevalence and management of tuberculosis infection in Apulian rheumatologic patients treated with biologics: An observational cohort 10-year study from the BIOPURE registry","volume":"53","author":"Fornaro","year":"2023","journal-title":"Eur J Clin Invest"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheumatol.2014.019","article-title":"Does isoniazid chemoprophylaxis increase the frequency of hepatotoxicity in patients receiving anti-TNF-\u03b1 agent with a disease-modifying antirheumatic drug","volume":"1","author":"Cansu","year":"2014","journal-title":"Eur J Rheumatol"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2009.10.012","article-title":"Frequency and tolerance of antituberculosis treatment according to national guidelines for prevention of risk of tuberculosis due to tumor necrosis factor blocker treatment","volume":"77","author":"Bray","year":"2010","journal-title":"Joint Bone Spine"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-007-0591-4","article-title":"Isoniazid intervention for latent tuberculosis among 86 patients with rheumatologic disease administered with anti-TNFalpha","volume":"26","author":"Hanta","year":"2007","journal-title":"Clin Rheumatol"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v9.i26.1092","article-title":"Risk of liver disease in methotrexate treated patients","volume":"9","author":"Conway","year":"2017","journal-title":"World J Hepatol"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2002.004598","article-title":"High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors","volume":"62","author":"Vanhoof","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-8-5","article-title":"Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study","volume":"8","author":"Goletti","year":"2007","journal-title":"Respir Res"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(21)00043-4","article-title":"Detection of Mycobacterium tuberculosis complex DNA in CD34-positive peripheral blood mononuclear cells of asymptomatic tuberculosis contacts: an observational study","volume":"2","author":"Belay","year":"2021","journal-title":"Lancet Microbe"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2024.106999","article-title":"Detection of Mycobacterium tuberculosis DNA in CD34+ peripheral blood mononuclear cells of adults with tuberculosis infection and disease","author":"Repele","year":"2024","journal-title":"Int J Infect Dis"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0306337","article-title":"Is yearly interferon gamma release assay latent tuberculosis infection screening warranted among patients with rheumatological diseases on disease-modifying drugs in non-endemic settings","volume":"19","author":"Palacios","year":"2024","journal-title":"PloS One"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1494283\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T01:35:07Z","timestamp":1738546507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1494283\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":194,"alternative-id":["10.3389\/fimmu.2025.1494283"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1494283","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,3]]},"article-number":"1494283"}}